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Research ArticleBile acids modulate glucocorticoid metabolism and the
hypothalamic–pituitary–adrenal axis in obstructive jaundiceq
Alison D. McNeilly1,*, David P. Macfarlane1, Emmett O’Flaherty1, Dawn E. Livingstone1, Tijana Mitic´1,
Kirsty M. McConnell1, Scott M. McKenzie2, Eleanor Davies2, Rebecca M. Reynolds1,
Helle C. Thiesson3, Ole Skøtt3, Brian R. Walker1, Ruth Andrew1
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Edinburgh EH16 4TJ, UK; 2MRC Blood Pressure Group, Glasgow Cardiovascular Research Centre, University of Glasgow,126 University Place,
Glasgow G12 8TA, UK; 3Physiology and Pharmacology, University of Southern Denmark, DK-5000 Odense C, DenmarkBackground & Aims: Suppression of the hypothalamic–pitui- urinary 3a,5b-reduced corticosterone. Cholestasis in rats sup-
tary–adrenal axis occurs in cirrhosis and cholestasis and is asso-
ciated with increased concentrations of bile acids. We
investigated whether this was mediated through bile acids acting
to impair steroid clearance by inhibiting glucocorticoid metabo-
lism by 5b-reductase.
Methods: The effect of bile acids on glucocorticoid metabolism
was studied in vitro in hepatic subcellular fractions and hepatoma
cells, allowing quantitation of the kinetics and transcript abun-
dance of 5b-reductase. Metabolism was subsequently examined
in vivo in rats following dietary manipulation or bile duct ligation.
Finally, glucocorticoid metabolism was assessed in humans with
obstructive jaundice.
Results: In rat hepatic cytosol, chenodeoxycholic acid competi-
tively inhibited 5b-reductase (Ki 9.19 ± 0.40 lM) and reduced
its transcript abundance (in H4iiE cells) and promoter activity
(reporter system, HepG2 cells).
In Wistar rats, dietary chenodeoxycholic acid (1% w/w chow)
inhibited hepatic 5b-reductase activity, reduced urinary excre-
tion of 3a,5b-tetrahydrocorticosterone and reduced adrenal
weight. Conversely, a fat-free diet suppressed bile acid levels
and increased hepatic 5b-reductase activity, supplementation of
the fat-free diet with CDCA reduced 5b-reductase activity, andJournal of Hepatology 20
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icosterone; GCMS, gas chromatography mass spectrometry; CDCA,
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Eagle’s medium; PCR, polymerase chain reaction; FF, fat-free; ECRP, endoscopic
retrograde cholangiopancreatography; ANOVA, analysis of variance; ALT, alanine
transaminase; ALP, alkaline phosphatase; Cyp11b1, 11b-hydroxylase; NEFA,
non-esteriﬁed fatty acids; SEM, standard error of mean.pressed hepatic 5b-reductase activity and transcript abundance.
In eight women with obstructive jaundice, relative urinary
excretion of 3a,5b-tetrahydrocortisol was signiﬁcantly lower
than in healthy controls.
Conclusion: These data suggest a novel role for bile acids in
inhibiting hepatic glucocorticoid clearance, of sufﬁcient magni-
tude to suppress hypothalamic–pituitary–adrenal axis activity.
Elevated hepatic bile acids may account for adrenal insufﬁciency
in liver disease.
Crown copyright  2010 Published by Elsevier B.V. on behalf of
the European Association for the Study of the Liver. All rights
reserved.Introduction
Activation of the hypothalamic–pituitary–adrenal (HPA) axis and
enhanced release of cortisol is crucial to a successful response to
stress, but this homeostatic mechanism is disrupted in liver dis-
ease. In cirrhosis, impaired responsiveness of the adrenal to ACTH
contributes to increased mortality with haemodynamic impair-
ment [1,2]. Replacement with low-dose hydrocortisone signiﬁ-
cantly improves resolution of shock and survival [3]. Similarly, in
cholestatic rats, secretion of corticotrophin-releasing hormone is
suppressed, and adrenal responses to stress are impaired [4]. How-
ever the cause of dysregulation of the HPA axis is not understood.
If metabolism of cortisol is impaired, then negative feedback
control of the HPA axis causes suppression of ACTH levels, atro-
phy of the adrenal gland and a reduced rate of production of cor-
tisol, a pattern also seen in cirrhosis [5,6]. As the liver is the major
site of cortisol metabolism [7], impaired clearance of cortisol in
liver disease may be caused by the reduced functional liver mass
or by an inhibitor of glucocorticoid metabolism.
Hepatic enzymes that inactivate glucocorticoids include 5a-
and 5b-reductases and 3a-hydroxysteroid dehydrogenase
(3aHSD), which convert cortisol into tetrahydrometabolites [8].
In addition, 5b-reductase and 3aHSD are involved in bile acid
synthesis [9]. Bile acids are cytotoxic, so their formation and
elimination are tightly regulated by the up-regulation of genes
encoding proteins that induce their detoxiﬁcation and/or10 vol. 52 j 705–711
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excretion, and by the suppression of genes (mainly through the
farnesoid X receptor (FXR)) encoding proteins that regulate cho-
lesterol catabolism, e.g., cholesterol 7a-hydroxylase (CYP7A1) [9].
Inhibition of renal 11bHSD2 by bile acids impairs glucocorti-
coid inactivation [10,11] and contributes to the sodium retention
and potassium wasting observed in cirrhosis and cholestasis [12]
as well as following bile duct ligation (BDL) [13], through illicit
occupation of mineralocorticoid receptors by excess cortisol. Bile
acids also inhibit hepatic 11bHSD1 [8,14–16], preventing gluco-
corticoid reactivation. Effects on glucocorticoid metabolism other
than by 11bHSDs have not been investigated, although inhibition
of 5b-reduction of aldosterone by bile acids has been demon-
strated [17].
We hypothesised that bile acid accumulation in cholestasis
inhibits hepatic 5b- reductase, contributing to impaired glucocor-
ticoid clearance and attenuation of HPA axis activity. The effects
of bile acids on the activity and transcription of hepatic 5b-reduc-
tase were investigated in vitro in liver and in hepatoma cells. The
effect of bile acids on HPA activity was assessed in vivo in rats fol-
lowing dietary manipulation [18] or BDL. Glucocorticoid metabo-
lism was also studied in humans following obstruction of the
common bile duct by gallstones.Materials and methods
Sources unless stated: solvents (Rathburn, Walkerburn, UK), cell culture reagents
(Gibco BRL, Paisley, UK), molecular biology reagents (Promega, Southampton,
UK), chemicals (Sigma–Aldrich, Poole, UK), radiochemicals (GE-Healthcare, Ayles-
bury, UK).
Effects of bile acids on enzyme kinetics in vitro
All experiments followed the guidelines of the Home Ofﬁce, UK or the Danish Ani-
mal Experiments Inspectorate. Male Wistar rats (9 weeks; Harlan Olac, Bicester,
UK) were sacriﬁced by decapitation (08:00 h) within 60 s of being disturbed.
[3H]4-Tetrahydrocorticosterone (5b-THB) (5b-reductase activity) was gener-
ated in hepatic cytosol (100 lg/ml protein), incubated 4 h with [3H]4-corticoste-
rone (25 nM), corticosterone (975 nM, IC50; 0.01–1000 lM, kinetics) and an
NADPH-generating system [19]. Conversion of 5b-dihydrocorticosterone (5b-
DHB; 2 lM) to 5b-THB (3aHSD activity) was measured following incubation
(10 min) as above. 5b-THB was quantiﬁed by gas chromatography mass spec-
trometry (GCMS) [20].
Bile acids (chenodeoxycholic acid (CDCA), cholic acid (CA), deoxycholic acid
(DCA), glyco-CDCA (GCDCA) or tauro-CDCA (TCDCA), (10–2–10–9M) were added
to incubations. Inhibition of velocity (IC50) was calculated relative to controls
without bile acid. Ki values were calculated by a global ﬁt model of competitive
inhibition (Kmapp = Km  (1 + I)/Ki; Y = Vmax  X/(Kmapp + X) using CDCA at its IC50.
Effect of bile acids on transcript abundance in cultured cells
H4iiE cells (ECACC, UK), were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM, Invitrogen, UK) supplemented with foetal calf serum (10% v/v), penicillin
(100 IU/ml), streptomycin (100 lg/ml), and L-glutamine (2 mM) (37 C, humidi-
ﬁed carbon dioxide:air (5:95)). Cells were transferred to fresh media 1 h prior
to the addition of bile acid (100 lM) or vehicle (ethanol, <1% v/v) and then incu-
bated (16 h) in triplicate. Total RNA was isolated using Trizol Reagent (Invitro-
gen, UK) and cDNA generated using First-Strand cDNA Synthesis Kit.
Quantiﬁcation of transcripts (normalised to cyclophilin A) was performed by
qPCR (PRISM 7900, Applied Biosystems, UK). Primers and probes were either
designed using Primer Express Software (5b-reductase, 3aHSD) or by Applied Bio-
systems (Cyp7a1, NM012942; cyclophilin A, NM017101).
Effect of bile acids on promoter activity of 5b-reductase
A fragment of the 50 untranslated region of hAKR1D1 (5b-reductase) representing
the region –383 to +446 kb (relative to transcription start site) [21] was cloned706 Journal of Hepatology 201from RPCI-11 HS BAC clone 386M10 (Invitrogen, UK). A construct was generated
using high-ﬁdelity PCR ampliﬁcation using the following oligonucleotides, incor-
porating a Kpn site (underlined) and conﬁrmatory sequencing performed.
50AKR1D1 (383), GGTACCAGTCCTGCTGCATCCAAATC;
30AKR1D1 (+446) GGTACCTGTGGAGAACCTGACTGTAGGA.
Amplimers were inserted into the multiple cloning site of the promoter-less
ﬁreﬂy luciferase reporter vector, pGL3-Basic, and their orientations were con-
ﬁrmed. Maxi DNA preparations of the luciferase construct were prepared using
Qiagen maxi kits (Crawley, UK).
The human hepatoblastoma cell line, HepG2 (ATCC, Rockville, USA), was cul-
tured in DMEM supplemented with foetal calf serum, L-glutamine and penicillin
as above. Plasmid DNA (10 lg) was transfected [22] into cells, along with
pCH110 plasmid (2 lg; b-galactosidase (b-Gal), Amersham, UK). CDCA (50 lM)
or ethanol was added 24 h after transfection. Luciferase activity was assayed in
cell lysates 72 h after transfection [23]. Transfection efﬁciency was assessed by
b-Gal activity assayed using the Tropix Galacto-Light kit (Cambridge Bioscience,
UK). Experiments were performed in triplicate three times utilising more than
one preparation of plasmid.Effects of bile acids in vivo in rats
Dietary manipulation of bile acids
Male Wistar rats (4–6 weeks; n = 8/group) were singly housed (6 days). In the
ﬁrst protocol, animals received standard chow ± CDCA (1% w/w, 4 weeks). In
the second, they received a fat-free (FF) diet (D05052506; Research Diets Inc,
USA) ± CDCA (1% w/w; D05052507) instead.
Daily production of glucocorticoids was studied in urine from animals
housed in metabolic cages for 6 days, after 3 weeks on their respective diets. In
the ﬁrst protocol only, responses to restraint stress were studied after 2.5 weeks
of the diet. Animals were acclimatised to handling (7 days) and then placed in
restraint tubes (20 min, 08:00) and returned to normal cages. Blood was obtained
at 0 (immediately prior to restraint) and at 20, 40, 60, and 90 min following
restraint.Bile duct ligation (BDL)
The common bile duct was ligated in male Wistar rats (n = 6/group; M&B Ejby,
Denmark) or rats subjected to sham surgery. Rats were sacriﬁced by decapitation
after 7 weeks, when jaundice and hepatosplenomegaly were evident and decom-
pensated liver failure had occurred [13].Ex vivo measurements
Enzyme activities were determined at the following substrate concentrations: 5b-
reductase (25 nM, 1 lM) and 3aHSD (1 lM). Plasma and hepatic biochemistry
and urinary steroids were quantiﬁed [19,20,24,25]. Bile acids were quantiﬁed
using a Total Bile Acid Kit (Trinity Biotech, Ireland) [26], and liver function tests
were quantiﬁed using a Modular P Analyser (Roche Diagnostics, Switzerland).
Transcripts of 5b-reductase and Cyp11b1 were quantiﬁed by qPCR [19,27] and
normalised to 18S RNA or b-actin (Applied Biosystems), respectively. Transcript
abundance of Cyp7a1 was quantiﬁed by northern blot analysis [24] and norma-
lised to U1 (M14386) [19].
Cortisol metabolism in obstructive jaundice in humans
With Local Ethical Committee approval (06/S1103/38) and written informed con-
sent, women (n = 8; 48.2 ± 7.0 y) were recruited following hospitalisation with
obstructive jaundice secondary to gallstone disease and studied prior to endo-
scopic retrograde cholangiopancreatography (ERCP). Healthy control women
(n = 5; 40.0 ± 7.4 y) were recruited by advertisement. Subjects receiving systemic
corticosteroid therapy within 3 months were excluded. Serum biochemical data
were recorded, and an overnight urine collection obtained the night before ERCP
and steroids was quantiﬁed by GCMS [28].
Statistical analysis
Results are mean ± SEM. In vitro data were analysed by ANOVA with post hoc
Fisher LSD tests. In vivo data were analysed by unpaired Student’s t tests or by
one-way or repeated measure ANOVA. Correlations were analysed by Pearson’s
product moment and partial correlation analyses.0 vol. 52 j 705–711
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Fig. 2. Effect of CDCA on transcription of steroid-metabolising enzymes. (A)
Abundance of mRNAs of rat 5b-reductase and Cyp7a1 but not 3aHSD was
suppressed in H4iiE cells by CDCA (100 lM), n = 5. (B) Activity of the promoter of
human 5b-reductase was reduced by CDCA (50 lM). Data are fold induction of
luciferase activity relative to control plasmid. (n = 3 triplicates), mean ± SEM;
*p <0.05, ***p <0.001 vs. vehicle.
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Results
Effects of bile acids on enzyme kinetics in vitro
5b-Reductase activity was inhibited signiﬁcantly by bile acids,
with an order of potency of CDCA = TCDCA = GCDCA > DCA > CA
(Fig. 1A–C). Bile acids and their conjugates did not inhibit 3aHSD
(14.29 ± 2.53 Control vs. 13.25 ± 3.02 CDCA; 13.87 ± 4.41 TCDCA;
18.44 ± 0.76 GCDCA nmol/mg/h). CDCA was a competitive inhib-
itor of 5b-reductase (Fig. 1D).
Effects of bile acids on mRNA levels of metabolising enzymes in vitro
CDCA reduced the transcript abundance of 5b-reductase (Fig. 2A)
and Cyp7a1 but not that of 3aHSD. CDCA also suppressed the
activity of the promoter of 5b-reductase (Fig. 2B).
Effects of CDCA supplementation in rats on standard chow diet
(Table 1)
CDCA increased the total bile acid content of plasma and faeces
and decreased hepatic Cyp7a1mRNA. CDCA reduced body weight
but not liver weight or glycogen content. CDCA tended to reduce
hepatic triglyceride content (p = 0.06), and it reduced plasma glu-
cose and insulin and increased plasma HDL cholesterol. CDCA-
treated animals had higher serum ALT vs. controls but exhibited
no change in ALP or albumin.Log Concentration (M)
Ki 9.19 ± 0.4 μM
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Fig. 1. Inhibition of 5b-reductase by bile acids. 5b-Reduction of corticosterone
in the presence of (A) CDCA, CA, DCA (B) CDCA, GCDCA, TCDCA. Velocity vs.
Control (100%), without bile acids. (C) IC50 of the reactions. (D) Lineweaver–Burke
plots showing competitive inhibition of 5b-reductase by CDCA (open squares:
2.5  10–6 M) (vs. vehicle (ﬁlled)). Mean ± SEM; n = 5. *p <0.05 vs. CDCA; #p <0.05
DCA vs. CA.
Journal of Hepatology 201Effects of CDCA on glucocorticoid metabolism
Hepatic 5b-reductase activity was reduced by CDCA, using 25 nM
substrate (Fig. 3A); this inhibition was overcome by substrate
concentrations of 1 lM (0.61 ± 0.14 Control vs. 0.56 ± 0.10 CDCA
nmol/mg/h). Activity did not correlate with LFTs (all p >0.10,
r < ± 0.39). CDCA did not alter 3aHSD activity or the abundance
of mRNAs encoding metabolising enzymes (Table 1).Effects of CDCA on the HPA axis and glucocorticoid action (Table 1)
CDCA reduced the excretion of 5b-THB, adrenal weight and adre-
nal Cyp11b1 (11b-hydroxylase) gene transcription. Baseline
plasma corticosterone levels were comparable between groups.
Following acute restraint, CDCA-treated animals had a delay in
the return to basal corticosterone levels (Fig. 4).Effects of removing bile acids with a fat-free diet and CDCA
supplementation in rats (Table 1)
An FF diet was administered to reduce hepatic bile acid concen-
tration; bile acid production rates were reduced (indicated by
faecal bile acids), but circulating levels were normal. The FF diet
was supplemented with CDCA (FF/CDCA) to test which effects of
the FF diet were attributable to bile acid deﬁciency. Supplemen-
tation suppressed hepatic Cyp7a1 and increased circulating and
faecal levels of bile acids.
The FF diet reduced liver weight, circulating glucose and insu-
lin and increased circulating triglycerides and NEFAs compared to
control. CDCA replacement reduced weight gain, decreased
plasma insulin and liver triglycerides and tended to decrease glu-
cose (p = 0.07), but it increased total and HDL-cholesterol com-
pared to the FF diet alone. The FF diet did not affect liver
function compared to controls; however, CDCA supplementation
in FF animals increased ALT but not ALP or albumin.0 vol. 52 j 705–711 707
Table 1. Physiological parameters following dietary manipulation.
Control CDCA Fat-free Fat-free/CDCA
BW change (g) 161.4 ± 7.1 121.9 ± 7.0* 197.1 ± 6.6* 174.3 ± 4.5#
Adrenal weight (mg/g BW) 0.082 ± 0.005 0.066 ± 0.005* 0.11 ± 0.003* 0.11 ± 0.003
Cyp11b1 copies mRNA/lg total RNA 9.13 ± 0.90  107 7.01 ± 0.74  107* 8.14 ± 1.59  107 4.40 ± 0.43  107#
Liver
Weight (mg/g BW) 45.3 ± 0.9 43.7 ± 1.06 38.2 ± 3.0* 33.3 ± 3.1
Glycogen (lmol/mg) 0.71 ± 0.15 0.68 ± 0.14 0.93 ± 0.09 1.07 ± 0.19
Triglycerides (mg/g) 14.7 ± 1.8 10.4 ± 1.5 18.6 ± 2.1 11.2 ± 1.6#
ALT (IU/L) 78 ± 6.5 211 ± 31.8* 36 ± 2.4 343 ± 118#
ALP (IU/L) 9.25 ± 3.9 30 ± 17.7 4 ± 0.6 5 ± 1.8
Albumin (g/L) 39 ± 1.3 41 ± 3.0 42 ± 1.3 40 ± 0.6
5b-Reductase mRNA/18S 0.79 ± 0.15 0.62 ± 0.04 0.42 ± 0.07 0.35 ± 0.04
3aHSD mRNA/18S 0.67 ± 0.18 1.02 ± 0.27 0.44 ± 0.75 0.61 ± 0.25
3aHSD activity (nmol/mg/hr) 6.22 ± 1.1 6.22 ± 0.6 9.55 ± 1.6 9.35 ± 2.1
Plasma
Corticosterone (nM) 78 ± 19 82 ± 26 85 ± 10 53 ± 7#
Glucose (mM) 8.4 ± 0.7 5.4 ± 0.7* 5.4 ± 0.6* 4.2 ± 0.5
Insulin (lg/L) 4.74 ± 0.60 2.87 ± 0.58* 3.05 ± 0.48* 1.78 ± 0.19#
Triglycerides (mM) 1.5 ± 0.2 1.3 ± 0.1 3.1 ± 0.3* 1.3 ± 0.2#
Cholesterol (mM) 1.89 ± 0.09 2.18 ± 0.11 1.81 ± 0.12 2.4 ± 0.1#
HDL cholesterol (mM) 1.33 ± 0.08 1.59 ± 0.09* 1.1 ± 0.1 1.6 ± 0.08#
NEFA (mM) 0.25 ± 0.03 0.27 ± 0.03 0.43 ± 0.04* 0.49 ± 0.06
Bile acids
Cyp7a1 mRNA/U1 1.36 ± 0.06 0.70 ± 0.03* 4.50 ± 0.56 2.78 ± 0.57#
Plasma (lM) 28.0 ± 8.7 73.6 ± 15.9* 31.9 ± 6.2 108.03 ± 16.4#
Hepatic (nmol/g) 84.3 ± 17.7 115.7 ± 16.4 25.1 ± 7.1* 34.8 ± 3.1
Faecal (lmol/day) 7.0 ± 0.8 12.5 ± 2.1* 1.0 ± 0.3* 5.3 ± 1.0#
Urinary steroids (ng/24 hr)
5b-THB 377 ± 68 213 ± 45* 305 ± 26 178 ± 22#
5a-THB 132 ± 32 187 ± 39 268 ± 49* 240 ± 27
Total 508 ± 77 400 ± 47 651 ± 116 392 ± 51#
CDCA, chenodeoxycholic acid; BW, body weight; ALT, alanine transaminase; ALP, alkaline phosphatase; Cyp11b1, 11b-hydroxylase; NEFA, non-esteriﬁed fatty acids; HSD,
hydroxysteroid dehydrogenase; Cyp7a1, cholesterol 7a-hydroxylase; THB, tetrahydrocorticosterone.
Mean ± SEM; *p <0.05 vs Control, #p <0.05 vs Fat-free.
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Fig. 3. In vivo elevation of bile acids inhibits hepatic 5b-reductase in rats. (A)
Hepatic 5b-reductase activity was inhibited in rats following dietary CDCA (ﬁlled)
vs. Control (open) and (B) following BDL (ﬁlled) vs. sham operation (open).
Mean ± SEM; *p <0.05 vs. Control, #p <0.05 vs. Fat-free (FF) diet, ***p <0.001 vs.
Sham.
Research ArticleEffects of FF ± CDCA on glucocorticoid-metabolising enzymes
5b-Reductase activity was greater on the FF diet than on chow,
while CDCA supplementation on an FF diet reduced 5b-reductase
activity when assayed with a substrate concentration of 25 nM708 Journal of Hepatology 201(Fig. 3A) but not 1 lM (0.51 ± 0.05 FF vs. 0.45 ± 0.10 FF/CDCA
nmol/mg/h). The activities of 5b-reductase did not correlate with
LFTs (all p >0.20, r < ±0.35). There were no differences between
groups in the activity of 3aHSD or in the levels of mRNAs for met-
abolising enzymes.
Effects of FF ± CDCA on glucocorticoid action and the HPA axis
FF diet did not affect urinary corticosterone metabolites com-
pared to Control animals. However, CDCA supplementation
reduced urinary total and 5b-reduced corticosterone metabolites
and also lowered the circulating concentration of corticosterone
(Table 1) compared to FF animals. The abundance of adrenal
Cyp11b1 mRNA was suppressed by CDCA.
Effects of BDL on steroid metabolism and synthesis in rats
Decompensated liver cirrhosis following BDL was conﬁrmed [13]
and was associated with elevated serum bile acids (111 ± 16;
p <0.05 vs. 22 ± 1.8 lM) compared to controls. Plasma corticoste-
rone was not altered by BDL (144 ± 39.6 vs. 112 ± 18.5 nM), and
adrenal weight was unchanged, as reported previously [13]. Ex
vivo metabolism of corticosterone by 5b-reductase was signiﬁ-
cantly impaired, with a substrate concentration of 25 nM
(Fig. 3B). This inhibition was overcome only partially using higher
(1 lM) concentrations of substrate (1.20 ± 0.3; p <0.05 vs.
4.32 ± 0.35 nmol/mg/h). Abundances of mRNAs for hepatic
5b-reductase and 3aHSD (Table 2) were reduced in the absence0 vol. 52 j 705–711
Table 2. mRNA transcripts of enzymes following BDL.
Sham BDL
Hepatic
5b-Reductase 9.07 ± 6.91 0.85 ± 0.60*
3aHSD 7.07 ± 3.60 0.55 ± 0.34**
Cyp7a1 2.11 ± 0.81 2.33 ± 0.56
Adrenal
Cyp11b1 8.25 ± 0.74 5.74 ± 0.76*
BDL, bile duct ligation; HSD, hydroxysteroid dehydrogenase; Cyp7a1, cholesterol
7a-hydroxylase; Cyp11b1, 11b-hydroxylase.
Hepatic genes corrected for 18S (unchanged between groups). Cyp11b1 is copy
no/lgRNA107.
Mean ± SEM; *p <0.05, **p <0.01.
Table 3. Urinary cortisol metabolites (lg/mg creatinine) in patients with
obstructive jaundice.
Obstructive jaundice Control
n 8 5
Cortisol 0.49 ± 0.13 0.11 ± 0.02
5b-THF 2.20 ± 0.89 2.49 ± 0.30
5a-THF 2.29 ± 0.78 2.95 ± 0.35
THE 6.39 ± 1.48 2.99 ± 0.32
5b-THF/5a-THF 1.45 ± 0.68 0.84 ± 0.02
5b-THF/cortisol 5.09 ± 1.36*** 20.11 ± 2.15
5a-THF/cortisol 8.88 ± 3.49* 23.77 ± 3.12
(5b-THF + 5a-THF)/THE 0.71 ± 0.15*** 1.82 ± 0.05
THF, tetrahydrocortisol; THE, tetrahydrocortisone.
Mean ± SEM. *p <0.05, ***p <0.001.
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JOURNAL OF HEPATOLOGYof changes in Cyp7a1 or 18S. Adrenal Cyp11b1 mRNA abundance
was reduced following BDL.
Effects of acute cholestasis on cortisol metabolism in humans
(Table 3)
Women with obstructive jaundice had elevated serum bilirubin
(142 ± 43 lM), ALT (287 ± 57 IU/L), ALP (500 ± 109 IU/L), c-glut-
amyl transferase (686 ± 213 IU/L), and bile acid (276 ± 51 lM)
concentrations, and the diagnosis of gallstone disease was con-
ﬁrmed at ERCP. Compared to controls, absolute excretion of the
major urinary cortisol metabolites was not different relative to
urinary creatinine, but those with obstructive jaundice excreted
a relatively lower proportion of total cortisol metabolites as 5b-
tetrahydrocortisol and had a less signiﬁcant reduction in relative
5a-tetrahydrocortisol excretion.Journal of Hepatology 201Discussion
This study shows that bile acids, particularly CDCA, are potent
competitive and transcriptional inhibitors of rat hepatic 5b-
reductase in vitro. Moreover, CDCA represses the activity of the
human 5b-reductase promoter. These effects were conﬁrmed to
be of physiological relevance in rat models in vivo. Manipulations
predicting increased hepatic bile acids caused impaired rates of
5b-reduction of glucocorticoids in tissue homogenates, which
were overcome ex vivowith excess substrate, suggesting compet-
itive inhibition. In contrast, 5b-reductase activity was increased
by feeding rats an FF diet (which lowered bile acid concentra-
tions), and this effect was reversed by CDCA supplementation.
These effects of bile acids also appear to be important in liver dis-
ease. In rats with cholestasis, 5b-reductase activity and transcrip-
tion were reduced, while in humans with biliary obstruction by
gallstones, there was a lower relative urinary excretion of 5b-
reduced cortisol metabolites. In several of these models, inhibi-
tion of 5b-reductase was accompanied by evidence of down-reg-
ulation of the HPA axis, with reduced total daily production rates
of glucocorticoids, lower production of 3a,5b-reduced metabo-
lites, and a reduction in adrenal weight and Cyp11b1 expression.
In vitro bile acids act as competitive inhibitors of enzymes in
the bile acid synthetic cascade [9], and they can also inﬂuence
the transcription of genes, often via interactions with FXR.
Although bile acids have been shown to inhibit 5b-reduction of
aldosterone in vitro [17], this study is the ﬁrst to show an inhibi-
tion of 5b-reduction of glucocorticoids both in vitro and in vivo.
CDCA, along with its conjugates, was the most potent bile acid
tested, with a Ki similar to its endogenous concentrations in the
enterohepatic circulation [9]. The effect was mediated through
competitive inhibition of the rate-determining enzyme, 5b-
reductase, and not via alterations in 3aHSD activity. CDCA resem-
bles many steroidal substrates for 5b-reductase, having a 3a,5b
conﬁguration, and thus may interact with the catalytic site [29].
The difference in potency between CDCA and other bile acids sug-
gests that the interactions with 5b-reductase are independent of
their detergent-like properties, but it may indicate that the
greater hydrophobicity of CDCA encourages interactions with or
without penetration into the active site. Although CA is the most
abundant bile acid in healthy rodents, CDCA becomes more abun-
dant in disease [30]. In cultured hepatoma cells, high concentra-
tions of CDCA also reduced the transcript abundance of only
5b-reductase and suppressed its promoter activity in transfection
studies. Preliminary examination of the 50 ﬂanking region of the
5b-reductase gene revealed an FXR-RXR consensus sequence at
+18 to +30, but functional activity of this site was not conﬁrmed0 vol. 52 j 705–711 709
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here. Of note, 5b-reductase has been identiﬁed as an FXR-respon-
sive gene by microarray [31].
Following short-term dietary manipulations in rats, inhibition
of 5b-reductase activity occurred in vivo in the absence of
changes in abundance of its mRNA or protein. The similar expres-
sion levels may be explained by the inhibition of 5b-reductase
activity being competed away by excess substrate ex vivo. In
other words, at the concentrations of bile acids achieved, it is
unlikely that the suppression of gene transcription observed
in vitro explains the reduction in 5b-reduced steroids in vivo.
Dietary administration of CDCA not only caused an increase in
hepatic and circulatory bile acid concentrations but also altered
liver function, inducing mild inﬂammation [32] without chole-
stasis. This might be a confounding effect, but, reassuringly,
the inhibition of glucocorticoid metabolism by CDCA was also
observed on an FF-diet background [18], where hepatic bile
acids and bile acid synthesis rates were reduced markedly com-
pared to normal chow, without altering liver function. The con-
sistency of our ﬁndings with the FF diet (in which there was no
hepatic inﬂammation) and with CDCA supplementation suggests
that the changes in glucocorticoid metabolism are mediated by
altered bile acid levels. Moreover, previous studies investigating
inﬂammatory hepatic conditions have demonstrated increased,
rather than decreased, 5b-reduction of glucocorticoids [33].
The extent of inhibition of steroid metabolism was more
marked in animals following BDL, in which suppression of the
HPA axis has been demonstrated [4]. In these animals, cholestasis
had developed, and liver function deteriorated. Circulating bile
acid concentrations were elevated following BDL. Unlike the die-
tary manipulations, BDL resulted in altered mRNA levels for
hepatic A-ring reductases, and reduced 5b-reductase expression
is supported by the inability of high concentrations of substrate
to fully overcome the inhibition of glucocorticoid metabolism
in this model. This suggests that, unlike the competitive inhibi-
tion of steroid-metabolising enzymes, the transcriptional effects
of bile acids are more important with the most extreme varia-
tions in bile acid concentrations. This ﬁnding was speciﬁc to
enzymes involved with steroid metabolism, not affecting Cyp7a1
[30] or 18S transcription, but it may reﬂect a difference in the
nature of the cellular composition of the liver, once ﬁbrotic dam-
age commences.
To our knowledge, this is the ﬁrst study to demonstrate the
consequences in vivo of alterations in hepatic glucocorticoid
metabolism by bile acids on HPA axis regulation. Basal circulating
concentrations of corticosterone were not altered with bile acid
treatment. However, suppression of the HPA axis was apparent
in the reductions in both adrenal size and 11b-hydroxylase gene
transcripts, as well as in the marked suppression in the daily pro-
duction rates of glucocorticoids, resulting in reduced amounts of
urinary steroids. The dynamic response of the HPA axis to
restraint stress was also different following treatment. Animals
receiving dietary CDCA were still able to mount a healthy peak
response, unlike cholestatic rats [4], perhaps due to the lesser
severity and duration of the insult. However, following dietary
CDCA, there was a signiﬁcant delay in the rate at which circulat-
ing corticosterone levels normalised, consistent with impaired
rates of clearance of the steroids by 5b-reduction. The impact of
CDCA on adrenal gland size was less evident on the FF diet; how-
ever, the feedback control of the HPA axis may have been altered
due to a non-speciﬁc effect of the high sucrose content of the FF
diet [34].710 Journal of Hepatology 201In patients who have been hospitalised, cortisol secretion is
usually demonstrably increased, especially at night. However,
consistent with down-regulation of the HPA axis, we did not ﬁnd
elevated absolute excretion rates of cortisol metabolites in
women admitted to the hospital with common bile duct obstruc-
tion. We did ﬁnd, however, that relative excretion of the major
5b-reduced cortisol metabolite, 5b-tetrahydrocortisol, was
decreased. It appears that 5b-reductase is not the only enzyme
disrupted in these patients; excretion of 5a-reduced cortisol
metabolites was also relatively low. Interestingly, although bile
acids are known to inhibit both isozymes of 11bHSD [8,14–16],
and inhibition of renal 11bHSD2 has been invoked as an explana-
tion for sodium retention in patients with liver disease, the ratio
of cortisol to cortisone metabolites was strikingly altered in
favour of cortisone metabolites in our patients. This suggests that
inhibition of A-ring reduction of cortisol and/or of 11bHSD1 is
more important than inhibition of renal 11bHSD2 (which would
elevate the cortisol/cortisone metabolite ratio). Moreover, as
illustrated in the rare condition of cortisone reductase deﬁciency
[35], loss of 11bHSD1 is associated with impaired regeneration of
cortisol from cortisone and a compensatory increase in HPA axis
activity. Because our patients exhibited a paradoxical failure to
increase cortisol secretion, we suggest that the inhibition of A-
ring reductases, and hence suppression of the HPA axis, is the
dominant effect. 5b-Reductase expression is suppressed by
androgens [36], and thus the inhibitory effects of bile acids may
be more obvious in women (in whom obstructive biliary disease
is more prevalent [37]).
In summary, the data presented here suggest an important
and novel role for bile acids in regulating the pattern and conse-
quences of glucocorticoid metabolism within the liver. The ele-
vated levels of bile acids arising during cholestasis may
contribute to the down-regulation of the HPA axis and hence
the apparent adrenal insufﬁciency associated with liver disease.
Therefore, sequestration of bile acids may be beneﬁcial at early
stages of this disease, not only to improve pruritis but also per-
haps to improve responsiveness to stress.
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